Presentation TCT 2017 Debate: After PCI in ACS, Should DAPT Potency Be De-escalated Over Time? Yes, Based on TROPICAL-ACS, TRITON, and Other Studies! Presenter: Dirk Sibbing October 30, 2017 REGISTER for free or LOG IN to view this content Coronary Presentation TCT 2017 CAD Pharma Up Next Presentation TCT 2017 Debate: After PCI in ACS, Should DAPT Potency Be De-escalated Over Time? No, Based on HORIZONS-AMI, PLATO, PEGASUS, and Other Studies! Presenter: Gennaro Giustino October 30, 2017 More slides + Presentation TCT 2017 XIENCE Everolimus-Eluting Stents: Device Iterations, Randomized/Registry Outcomes Data in Perspective and the Move to Shorter DAPT Presenter: Tullio Palmerini October 30, 2017 Presentation TCT 2017 Promus Element Everolimus-Eluting Stents: Device Iterations and Randomized/Registry Outcomes Data in Perspective Presenter: Sigmund Silber October 30, 2017 We Recommend
Presentation TCT 2017 Debate: After PCI in ACS, Should DAPT Potency Be De-escalated Over Time? No, Based on HORIZONS-AMI, PLATO, PEGASUS, and Other Studies! Presenter: Gennaro Giustino October 30, 2017
Presentation TCT 2017 XIENCE Everolimus-Eluting Stents: Device Iterations, Randomized/Registry Outcomes Data in Perspective and the Move to Shorter DAPT Presenter: Tullio Palmerini October 30, 2017
Presentation TCT 2017 Promus Element Everolimus-Eluting Stents: Device Iterations and Randomized/Registry Outcomes Data in Perspective Presenter: Sigmund Silber October 30, 2017